

Keith D. Jensen, Ph.D.

7 Bradley Road
Arlington, MA 02474
Work@DCKJ.com
KDJ@MIT.edu

Cell: 617-599-6241
CV on-line: www.DCKJ.com/cv
LinkedIn: <http://www.linkedin.com/in/keithjensen/>

Summary

- Highly conscientious, results-orientated, hands-on leader
- Over 16-years pharma experience specializing in continuous manufacturing of pharmaceuticals and early to late-stage solid dosage formulation development
- Leader of high-performing teams applying expertise in fundamental pharmaceutical scientific principles to rationally finding solutions to various formulation and process challenges resulting in viable and robust products

Experience

Owner and Independent Pharmaceutical Consultant (June 2017—present): **Keith Jensen Consulting**

- Consulting on formulation and processing of oral and medical device/drug products
- World leader on thin film formulation and processing
- Expert on continuous manufacturing of pharmaceutical drug products
- Scientific advisor for pharmaceutical companies
- Expert witness in patent litigation



USP Expert Panel on Continuous Manufacturing (Nov 2016—present):

The United States Pharmacopeial Convention, Rockville, Maryland.

- Active and inaugural member of the USP Quality Standards for Pharmaceutical Continuous Manufacturing Expert Panel
- Provide the USP with Continuous Manufacturing expertise
- Co-author guidance publications on Continuous Manufacturing
- Propose and promote research on Continuous Manufacturing
- Part of first group to propose chapters on Continuous Manufacturing in the USP



Associate Director & Principal Investigator (Feb 2014—May 2017):

Novartis-MIT Center for Continuous Manufacturing, Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, Supervisors: Bernhardt L. Trout, Allan Myerson.

- Led a team of 13 researchers (Staff Engineers, Post-doctoral Fellows, Graduate Students) and worked with most of the 12 professors and their research groups in the Novartis-MIT Center.
- Four major projects: novel methods to continuously manufacture tablets in the most direct and simple path (minimize the number of unit operations for problematic drugs)
 - Continuous heterogeneous crystallization of API on excipients for direct compression
 - Crystallize problematic drugs (e.g. needles, poor flowability, etc.) directly onto excipients so that the excipient controls the particle morphology and properties
 - Simplifies filtration and drying
 - **Enables direct compression of problematic drugs**
 - **2 Patent applications filed**



Keith D. Jensen, Ph.D.

- Tableting of API containing thin films
 - Drug containing thin films are produced via solvent casting and drying
 - Film is folded and compressed into a tablet/caplet
 - **Patent disclosure in preparation**
- Integrated hot-melt extrusion, injection molding, and mold coating of tablets
 - Use HME to simplify tableting of problematic drugs
 - HME is directly coupled to injection molding machine
 - *Tablets are injection molded* (no powder compaction) from molten extrudate
 - Molded tablets are then *coated via coupled injection molding*
 - **Patent application filed**
- Tableting of electrospun mats containing API
 - Drug containing mats are produced via free-surface electrospinning
 - Mats are continuously and directly processed into tablets/caplets
 - **Patent disclosure in preparation**
- Organizing committee member of the 1st and 2nd International Symposium on Continuous Manufacturing of Pharmaceuticals.
- 4 Invited talks, 5 Patent disclosures/applications, +8 Articles, 8 Posters.
- Help manage Center finances (~\$8.5 M/yr), my group's budget: ~\$1.5 M/yr

Formulation Manager, Oral Systems (2003-2014):

LTS Lohmann Therapy Systems, West Caldwell, New Jersey.



Formulation development:

- Successfully developed and managed 9 major projects and 23 minor projects in 10 years (80% Rx, 20% OTC) culminating in 7 clinical studies (5 human, 1 canine, 1 hamster)
 - Sourcing, evaluating, and selecting raw materials
 - Utilized DOE's in formulation testing following QbD principles
 - **Increased bioavailability from <1% to 70-75%** (Global Patents Filed, Patent already granted in USA, Germany, and Panama).
 - **Increased bioavailability of another API with both very poor aqueous solubility and severe first-pass effect (+98% liver degradation) by 13,000%** (patent pending)

Scale up/tech transfer/process development:

- **Joint responsibility in the installation, qualification, validation, and day to day operations of a new small-scale R&D manufacturing suite—2-25 kg**
- Managed and scaled-up numerous formulations to 15-25 kg scale
- Organized and manufactured clinical samples according to cGMP / GLP for 7 clinical trials
- Successfully managed the scale-up of 3 formulations to 80-100 kg scale in production
- Designed and executed numerous QbD studies on the effect of excipient selection and levels, equipment, manufacturing processes, and packaging materials on the products

Scientific expertise:

- Subject Matter Expert in oral thin films (strips) and buccal permeation; I was sought after by Business Development to present at client and conference meetings.
- +20 years of scientific research which began as undergraduate research in Chemistry honing my critical thinking, problem solving, decision making, reporting, and presenting skills
- Mentor to junior scientists from Associate degree to Ph.D.

Leadership/Management experience:

- Responsibilities continuously increased from when I joined as a Ph.D. scientist, to complete management of cross-functional teams in complex and rapidly changing programs
- Primary contact for clients concerning all project aspects
- Mentored and developed a formulation group; the Ph.D. scientist reporting to me was promoted to my level in 1½ years

Keith D. Jensen, Ph.D.

- Strategic thinker and collaborator responsible for the development and complete projects
- Responsible for risk evaluation and management of lead formulations as well as root cause analysis of formulation and manufacturing process problems

Analytical/in vitro testing:

- Broad background in analytical chemistry and separation sciences
- Expertise in many forms of microscopy, numerous separation techniques, and spectroscopic determinations. Experience with rheometry, DMA, DSC, and laser light scattering (more info on-line: [Internet CV-Techniques](#))
- Designed and executed *in vitro* permeation studies using artificial membranes, *ex vivo* animal tissue, and cell culture generated "buccal tissue"

Compliance:

- Primary responsibility for CMC section and author of all formulation sections in 7 IMPD/IND's
- Authored numerous SOP's, GXP batch records, stability protocols, and technical reports complying with ICH, FDA, and EMA guidelines

Education

Ph.D. in Pharmaceutics and Pharmaceutical Chemistry: University of Utah



UNIVERSITY OF UTAH
COLLEGE OF PHARMACY

Honors Bachelor of Science in Chemistry (Minor in German): University of Utah



Summer Study Abroad (German): Technische Universität Braunschweig, Germany

Awards

- First author of paper receiving the AAPS PharmSci & AAPS PharmSciTech Outstanding Use of Technology Award
- Walter F. Enz Award in Pharmaceutics from Pharmacia & Upjohn
- Nagai Foundation Tokyo CRS Graduate Student Award
- American Foundation of Pharmaceutical Education Pre-Doctoral Fellowship
- NIH Biological Chemistry Training Fellowship
- Higuchi Fellowship in Pharmaceutics
- Walter D. and Grace Bonner Memorial Award in Chemistry
- Leon Watters Memorial Award for achievement in Chemistry
- University of Utah Liberal Education Study Abroad Scholarship
- Leon Watters Memorial Award for achievement in Chemistry
- University of Utah Chemistry Department Four-Year Scholarship

Skills

Scientific, Problem Solving, and Goal Orientated: a broad and thorough knowledge and experience in pharmaceutical product research and development gained through innovative research at MIT with the world leaders in continuous manufacturing and developing numerous oral solid dosage products. This has honed my ability to dissect large problems into precise objectives. These objectives were systematically explored to reach solutions and improve formulations resulting in robust formulation, processes, and products.

Leadership, Collaboration, and Teamwork: at MIT I mentored and directed a large group of Engineers and Post-docs (8 direct reports, 5 indirect reports) as well as informal mentoring of graduate students and interns. At LTS, I led a team which ranged from members having an associate's degree to a Ph.D. I was able to prepare the Ph.D. to be promoted to manager in 1½ years. I progressed to become the project manager of various internal and external teams for projects and work organizations, an organizer, and a leader of partner teams to complete projects. I also have prior experience as a teaching assistant, mentor to two graduate students, and collaborations with widely varying people in commercial, academic, and religious environments.

Oral and Written Communication: authored/coauthored/presented many patent disclosure/applications, journal articles, several CMC sections of IMPDs, a Ph.D. dissertation, a Senior Honors Thesis, numerous abstracts, many SOPs, monthly reports, and numerous oral presentations to partner companies, seminars, and group meetings.

Professional Affiliations and Honor Societies

- American Association of Pharmaceutical Scientists
- Controlled Release Society
- American Institute of Chemical Engineers
- American Chemical Society
- Phi Kappa Phi
- Phi Beta Kappa
- Delta Phi Alpha
- Sigma Xi, The Scientific Research Society

Patents

1. Patent Disclosure on processing electrospun mats into tablets (*actual title withheld until publication*). Alex Martinez, David Brancazio, Rachael Hogan, Keith D. Jensen, Bernhardt L. Trout. (in Preparation).
2. Patent Disclosure on folding of films for continuous tableting (*actual title withheld until publication*). Forrest Whitcher, Keith D. Jensen, David Brancazio, Bernhardt L. Trout. (in Preparation).
3. Patent application on continuous crystallization for tableting on excipients (*actual title withheld until publication*). Nima Yazdan Panah, Jelena Stojakovic, Keith D. Jensen, Allan S. Myerson, Bernhardt L. Trout. (Provisional patent application submitted to USPTO).
4. Pharmaceutical Tablet Coating Process by Injection Molding Process Technology. Vibha Puri, Parind M. Desai, Keith D. Jensen, David Brancazio, Eranda Harinath, Alex R. Martinez, Jung-Hoon Chun,

Keith D. Jensen, Ph.D.

- Richard D. Braatz, Allan S. Myerson, Bernhardt L. Trout. US Patent Application: 15/620,568, (June 12, 2017).
5. *Methods and Systems for Continuous Heterogeneous Crystallization*. Bernhardt L. Trout, Allan S. Myerson, Siva R. K. Perala, Christopher J. Testa, Keith D. Jensen. US Patent Application: 15/054,956, (Feb. 26, 2016).
 6. *Transmucosal Administration System for a Pharmaceutical Drug*. Markus Krumme, Keith Jensen, Judith Dubach-Powell, Rudolf Hausmann. US Patent Application 20140377312 (January 17, 2013). ([Link to patent abstract](#))
 7. *Wafer Comprising Steroid Hormones*. Markus Krumme, Albert Radlmaier, Sascha General, Michael Dittgen, and Keith Jensen. US Patent Number 9,763,960 (October 5, 2006). The patent has already been granted in the USA, Germany, and Panama, patents were globally filed. ([Link to patent abstract](#))
 8. *Dry, Redispersible, Biodegradable Latexes for Use as MRI Imaging Agents and Drug Carriers*. Peter J. Tarcha, Ronald Morgan, and Keith D. Jensen. Patent Disclosure #19631 assigned to Abbott Laboratories (1997).

Publications

1. *Regulatory Perspectives on Continuous Pharmaceutical Manufacturing: Moving from Theory to Practice September 26-27, 2016, International Symposium on the Continuous Manufacturing of Pharmaceuticals*. Moheb M. Nasr, Markus Krumme, Yoshihiro Matsuda, Bernhardt L. Trout, Clive Badman, Salvatore Mascia, Charles Cooney, Keith D. Jensen, Alastair Florence, Craig Johnson, Konstantin Konstantinov, and Sau (Larry) Lee. *Journal of Pharmaceutical Sciences*. **106** (2017) 3199-3206. ([Link](#))
2. *End-to-End Continuous Manufacturing: Integration of Unit Operations* (book chapter) in *Continuous Manufacturing of Pharmaceuticals (Advances in Pharmaceutical Technology)*. Richard Lakerveld, Patrick L. Heider, Keith D. Jensen, Richard D. Braatz, Klavs F. Jensen, Allan S. Myerson, and Bernhardt L. Trout. Editors: P. Kleinebudde, J. Khinast, J. Rantanen. John Wiley & Sons, Hoboken, NJ, pp. 447-483. (Sept, 2017). ([Link to Chapter](#))
3. *Continuous Heterogeneous Crystallization on Excipient Surfaces*. Nima Yazdanpanah, Christopher J. Testa, Siva R. K. Perala, Keith D. Jensen, Allan S. Myerson, Bernhardt L. Trout. *Crystal Growth & Design*, **17** (6), (2017) 3321–3330. ([Link](#))
4. *Development of Maltodextrin Based Immediate Release Tablets using an Integrated Twin-Screw Hot Melt Extrusion and Injection Molding Continuous Manufacturing Process*. Vibha Puri, David Brancazio, Parind Desai, Eranda Harinath, Alex Martinez, Keith D. Jensen, Jung-Hoon Chun, Richard D. Braatz, Allan S. Myerson, Bernhardt L. Trout. *Journal of Pharmaceutical Sciences*. **106** (2017) 3328-3336. ([Link](#))
5. *Water-soluble Placebo Polymer Thin Films for Continuous Manufacturing of Tablets*. Aishuang Xiang, Hannah K. Fitch, Keith D. Jensen, Allan S. Myerson, Bernhardt L. Trout. (Submitted).
6. *Dimensional Stability and Product Robustness of Injection Molded Maltodextrin Based Griseofulvin Tablets*. Parind Desai, Vibha Puri, Keith D. Jensen, Jung-Hoon Chun, Allan S. Myerson, Bernhardt L. Trout. *International Journal of Pharmaceutics*. **531** (1), (2017) 332-342. ([Link](#))
7. Article on processing electrospun mats into tablets (*actual title withheld until publication*). Alex Martinez, David Brancazio, Rachael Hogan, Keith D. Jensen, Bernhardt L. Trout. (In Preparation).

Keith D. Jensen, Ph.D.

8. *Tablet Coating by Injection Molding Technology--Optimization of Coating Formulation Attributes and Coating Process Parameters.* Parind Desai, Vibha Puri, [Keith D. Jensen](#), Jung-Hoon Chun, Allan S. Myerson, Bernhardt L. Trout. *European Journal of Pharmaceutics and Biopharmaceutics*, **122** (2017) 25-36. ([Link](#))
 9. *Confocal Microscopy Studies of a Model Oligoribonucleotide HIV Inhibitor.* Robyn M. Hyde, [Keith Jensen](#), Jindrich Kopecek, and Arthur D. Broom. *Nucleosides, Nucleotides, and Nucleic Acids*, **24** (2005) 1875–1884. ([Link](#))
 10. *Subcellular Trafficking of HPMA Copolymer-Tat Conjugates in Human Ovarian Carcinoma Cells.* Aparna Nori, [Keith D. Jensen](#), Monica Tijerina, Pavla Kopeckova, Jindrich Kopecek. *Journal of Controlled Release*, **91** (1-2), (2003) 53-59. ([Link](#))
 11. *Cytoplasmic Delivery and Nuclear Targeting of Synthetic Macromolecules.* [Keith D. Jensen](#), Aparna Nori, Monica Tijerina, Pavla Kopeckova, and Jindrich Kopecek. *Journal of Controlled Release*, **87** (1-3), (2003) 89-105. ([Link](#))
 12. *TAT-Conjugated Synthetic Macromolecules Facilitate Cytoplasmic Drug Delivery to Human Ovarian Carcinoma Cells.* Aparna Nori, [Keith D. Jensen](#), Monica Tijerina, Pavla Kopeckova, and Jindrich Kopecek. *Bioconjugate Chemistry*, **14** (1), (2003) 44-50. ([Link](#))
 13. *Antisense Oligonucleotides Delivered to the Lysosome Escape and Actively Inhibit the Hepatitis B Virus.* [Keith D. Jensen](#), Pavla Kopeckova, and Jindrich Kopecek. *Bioconjugate Chemistry*, **13**, (5), (2002) 975-984. ([Link](#)) **Selected as cover article.**
 14. *The Internalization and Fate of HPMA Copolymers and Antisense-HPMA Copolymer Conjugates in Hep G2 Cells.* [Keith D. Jensen](#). Dissertation for Ph.D. in Pharmaceutics and Pharmaceutical Chemistry, University of Utah, August 2002. ([Link to Abstract](#))
 15. *The Cytoplasmic Escape and Nuclear Accumulation of Endocytosed and Microinjected HPMA Copolymers and a Basic Kinetic Study in Hep G2 Cells.* [Keith D. Jensen](#), Pavla Kopeckova, John H. B. Bridge, and Jindrich Kopecek. *AAPS PharmSci*, **3** (4), (2001) article 32. ([Link](#))
Article awarded the AAPS Manuscript Award for Outstanding Use of Technology.
 16. *The Influence of Cytotoxicity of Macromolecules and of VEGF Gene Modulated Vascular Permeability on the Enhanced Permeability and Retention Effect in Resistant Solid Tumors.* Tamara Minko, Pavla Kopeckova, Vitaliy Poxharov, [Keith D. Jensen](#), and Jindrich Kopecek. *Pharmaceutical Research*, **17**, (2000) 505-514. ([Link](#))
 17. *High Speed Particle Separation and Steric Inversion in Thin Flow Field-flow Fractionation Channels.* [Keith D. Jensen](#), S. Kim R. Williams, and J. Calvin Giddings. *Journal of Chromatography A*, **746** (1996) 137-145. ([Link](#))
 18. *Field-flow Fractionation in the Hyperlayer Inversion Region.* [Keith D. Jensen](#). Senior Thesis for the Honors Degree of Bachelor of Science in Chemistry, University of Utah, August 1993. ([Link to Abstract](#))
-

Presentations/Posters

1. *Innovations & Breakthroughs in Continuous Crystallization Processing*. Keith D. Jensen. Invited Oral Presentation at the Commercializing Continuous Manufacturing in Pharma. Boston, Massachusetts, Jan. 30-Feb 1, 2017.
2. *Tablet Coating by Injection Molding Technology*. Parind M. Desai, Vibha Puri, David Brancazio, Alex R. Martinez, Jeremy E. Hartman, Keith D. Jensen, Eranda Harinath, Richard D. Braatz, Jung-Hoon, Chun, Allan S. Myerson, Bernhardt L Trout. 2016 Annual Meeting of the American Association of Pharmaceutical Scientists, Denver, Colorado, November 13-17, 2016, Abstract # 22W0100.
3. *Dimensional Stability of Injection Molded Maltodextrin Based Griseofulvin Tablets*. Parind M. Desai, Rachael C. Hogan, David Brancazio, Jeremy E. Hartman, Vibha Puri, Keith D. Jensen, Jung-Hoon, Chun, Allan S. Myerson, Bernhardt L Trout. 2016 Annual Meeting of the American Association of Pharmaceutical Scientists, Denver, Colorado, November 13-17, 2016, Abstract # 22M0200.
4. *Water-soluble Placebo Polymer Thin Films for Continuous Manufacturing of Tablets*. Aishuang Xiang, Keith D. Jensen, Hannah K. Fitch, Allan S. Myerson, Bernhardt L Trout. 2015 Annual Meeting of the American Association of Pharmaceutical Scientists, Orlando, Florida, October 25-29, 2015, Abstract #W5317.
5. *Development of Immediate Release Tablets by Integrated Hot Melt Extrusion and Injection Molding Process Technology: A Potential Platform for Continuous Pharmaceutical Manufacturing*. Vibha Puri, David Brancazio, Keith D. Jensen, Jung-Hoon Chun, Allan S. Myerson, Bernhardt L. Trout. 2015 Annual Meeting of the American Association of Pharmaceutical Scientists, Orlando, Florida, October 25-29, 2015, Abstract #M1022.
6. *Continuous Heterogeneous Crystallization of Active Pharmaceutical Ingredients on Excipient Surfaces*. Christopher J. Testa, Siva R. K. Perala, Keith D. Jensen, Bernhardt L. Trout, Allan S. Myerson. 2015 Annual Meeting of the American Association of Pharmaceutical Scientists, Orlando, Florida, October 25-29, 2015, Abstract #W5295.
7. *Three Aspects of Modernizing Pharmaceutical Product Manufacturing: Continuous, QbD, and PAT*. Keith D. Jensen. Invited Oral Presentation at the Seventh pan-European Science Conference on QbD and PAT Sciences – Inventing Tomorrow's Development and Manufacturing. Graz, Austria, May 18-19, 2015.
8. *Continuous Manufacturing and Its Implementation into the Pharmaceutical Industry: An Academic Perspective*. Keith D. Jensen. Invited Oral Presentation at the 50th AAPS Arden Conference on Continuous Manufacturing of Solid Oral Drug Products, 2015. Baltimore, Maryland, March 16-18.
9. *Continuous Manufacturing: The Bridge to the Future?* Keith D. Jensen. Invited Oral Presentation at the strategy& Pharma Executive Roundtable 2014, Frankfurt, Germany, September 25, 2014.
10. *Continuous Downstream Manufacturing via Free-surface Electrospinning*. Indrani Bhattacharyya, Rachael C. Hogan, Keith D. Jensen, Gregory C. Rutledge. 1st International Symposium on Continuous Manufacturing of Pharmaceuticals, MIT, Cambridge, Massachusetts, May 20-21, 2014.
11. *Advantages of Oral Thin Film Strips*. Keith D. Jensen. Invited Oral Presentation at the Thirteenth Annual Drug Delivery Partnerships, Las Vegas, NV, Jan 21-23, 2009.
12. *Cytoplasmic Delivery and Nuclear Targeting of Synthetic Macromolecules*. Aparna Nori, Monica Tijerina, Keith D. Jensen, Pavla Kopeckova, and Jindrich Kopecek. Seventh European Symposium on Controlled Drug Delivery, Noordwijk ann Zee, Netherlands, April 3-5, 2002, *Proceedings*, p. 31

Keith D. Jensen, Ph.D.

13. *Cytoplasmic Delivery and Nuclear Targeting of HPMA Copolymer-TAT Conjugates to Human Ovarian Carcinoma Cells.* Aparna Nori, Keith D. Jensen, Monica Tijerina, Pavla Kopeckova, and Jindrich Kopecek. 28th International Symposium on Controlled Release of Bioactive Materials, San Diego, California, June 23-27, 2001, Abstract #6122.
14. *The Influence of Cytotoxicity of Macromolecules on the EPR Effect in Resistant Solid Tumors.* Pavla Kopeckova, Tamara Minko, Keith D. Jensen, and Jindrich Kopecek. Fourth International Symposium on Polymer Therapeutics, London, England, January 5-7, 2000, *Programme and Proceedings*, p. 53
15. *Studying the Fate of Antisense Oligonucleotide/Polymer Conjugates Targeted to Hep G2 Cells.* Keith D. Jensen, Pavla Kopeckova, and Jindrich Kopecek. 14th Annual Meeting of the American Association of Pharmaceutical Scientists, New Orleans, Louisiana, November 14-18, 1999, *AAPS PharmSci*, **1** (4) Abstract #4099.
16. *Study of the Internalization and Subcellular Trafficking of Model Antisense Compounds in Hep G2 Cells.* Keith D. Jensen, Pavla Kopeckova, and Jindrich Kopecek. 25th International Symposium on Controlled Release of Bioactive Materials, Las Vegas, Nevada, June 21-24, 1998, *Proceedings*, pp. 352-353, Abstract #5009.
17. *A Hepatocyte Targeted Antisense Oligonucleotide Delivery System Using Copolymers of N-(2-Hydroxypropyl)Methacrylamide.* Keith D. Jensen, Pavla Kopeckova, and Jindrich Kopecek. 12th Annual Meeting of the American Association of Pharmaceutical Scientists, Boston, Massachusetts, November 2-6, 1997, *Pharm. Res.*, **14** (11 supplement), S-55, Abstract #1169.
18. *Aspects in the Development of Polyanhydride Sustained Drug Delivery Devices.* Keith D. Jensen, Peter Tarcha, Youqin Tian, Dennis Stephens, H.C. Chang, Shen Chen, and Luk Li. Center for Biopolymers at Interfaces Semi-Annual Business Meeting, Salt Lake City, Utah, September 22-24, 1996, Abstract #18.
19. *Steric Inversion and High Speed Crossflow Field-flow Fractionation Analysis.* Keith D. Jensen, S. Kim Ratanathanawongs, and J. Calvin Giddings. Fifth International Symposium on Field-flow Fractionation, Park City, Utah, July 10-12, 1995, *Proceedings*.
20. *Lowering the Steric Transition Diameter and Fast Separations in Field-flow Fractionation.* Keith D. Jensen, S. Kim Ratanathanawongs, and J. Calvin Giddings. Seventh National Conference on Undergraduate Research, University of Utah, April, 1993, *Proceedings*.
21. *Field-flow Fractionation of Particles in the Steric Inversion Region.* Keith D. Jensen, S. Kim Ratanathanawongs, and J. Calvin Giddings. Sixth National Conference on Undergraduate Research, University of Minnesota, Minneapolis, Minnesota, March 26-28 1992, *Proceedings*, Abstract #992.
22. *Manipulation of the Steric Transition Diameter in Flow FFF.* Keith D. Jensen, S. Kim Ratanathanawongs, and J. Calvin Giddings. Third International Symposium on Field-flow Fractionation, Park City, Utah, October, 1992, *Proceedings*.

Volunteer and Other Experience

- Men's group leader at my local church (Current)
- Numerous past responsibilities at local church
- Previous Boy Scout Assistant Scoutmaster
- Previous Head Start Volunteer
- Eagle Scout

Keith D. Jensen, Ph.D.

Languages

Fluent in Spanish and German

References available upon request

CV on-line: www.DCKJ.com/cv